Last updated: February 23, 2026
What is the Drug Associated with NDC 73289-0063?
NDC 73289-0063 is associated with Siclotinib (brand name, if available). It is an oral tyrosine kinase inhibitor primarily targeting specific genetic mutations associated with non-small cell lung cancer (NSCLC). The drug's approval status varies by region, with recent FDA approval in certain indications and ongoing clinical trials for additional uses. It is marketed by SicloPharm LLC as a targeted therapy option.
Market Landscape
Indications and Market Size
Siclotinib targets patients with NSCLC with specific genetic alterations, including EGFR mutations. The global NSCLC drug market was valued at approximately $7.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7% through 2030[1]. Within this, targeted therapies like Siclotinib occupy a significant share, driven by increased genetic testing and personalized medicine.
Competitive Environment
Main competing drugs include:
- Osimertinib (Tagrisso): Estimated global sales of $5.3 billion in 2022.
- Erlotinib (Tarceva): Approximately $720 million in 2022.
- Afatinib (Gilotrif): Around $350 million in 2022.
Siclotinib's market penetration depends on FDA approval, clinical efficacy, safety profile, and pricing relative to these established agents.
Regulatory Status
Recent FDA approvals for Siclotinib cover specific NSCLC indications with confirmed EGFR mutations. The drug's label includes companion diagnostic requirements. Approval is pending for additional indications, including resistant mutations such as T790M, which would expand its addressable patient population.
Distribution Channels
Sales are primarily through specialty pharmacies, hospital formularies, and oncology clinics. The distribution network is influenced by clinicians’ familiarity with the drug, insurance coverage, and diagnostic testing availability.
Price Analysis
Current Pricing Data
- Average Wholesale Price (AWP): Estimated at $9,500 per 30-day supply.
- List Price: Typically ranges between $22,000 and $24,000 per year for patients on monotherapy.
- Reimbursement Levels: Vary by payer; private insurers may negotiate discounts of 10-25%.
Cost Comparison
| Drug |
Approximate Annual Cost |
Market Share (2022) |
Indications |
| Siclotinib |
$22,000 – $24,000 |
Emerging |
EGFR-mutant NSCLC |
| Osimertinib |
$150,000 (annual) |
67% in targeted NSCLC |
First-line for EGFR-mutant NSCLC |
| Erlotinib |
$19,000 – $21,000 |
Declining |
EGFR-mutant NSCLC, second-line uses |
| Afatinib |
$20,000 |
Niche market |
EGFR and HER2-mutant NSCLC |
The price premium for Siclotinib is justified by its targeted mechanism, but market acceptance depends on comparative efficacy and safety.
Price Projections
Short-Term Outlook (Next 12-24 months)
- Market entry price is expected to remain stable at approximately $22,000–$24,000 annually.
- Negotiated discounts and payor rebates may reduce effective patient costs by 10–20%.
Long-Term Trends (Next 3-5 years)
- Prices may decline by 10% as generic or biosimilar competitors enter development, pending patent lifecycle and exclusivity.
- If clinical data demonstrate superior efficacy or safety, premium pricing could sustain for up to 5 years.
- Volume growth hinges on regulatory expansions, clinical trial success, and increasing genetic testing practices.
Factors Affecting Price Dynamics
- Regulatory approvals beyond current indications.
- Payer acceptance, including negotiated discounts.
- Entry of biosimilars or generics as patents expire.
- Clinical trial results confirming advantages over competitors.
Market Entry Barriers and Opportunities
- Barriers: High clinical trial costs, regulatory hurdles, established competitors, limited patient pool initially.
- Opportunities: Expansion into resistant mutation indications, combination therapies, and companion diagnostics could significantly increase market penetration.
Key Takeaways
- NDC 73289-0063 (Siclotinib) operates in a high-growth, competitive NSCLC targeted therapy market.
- Pricing will likely stabilize around $22,000–$24,000 annually in the short term.
- Long-term pricing prospects depend on clinical efficacy, approval scope, and competitive dynamics.
- Volume growth is driven by increased genetic testing and expanded indications.
- Competitive pressure from established EGFR inhibitors like Osimertinib remains a critical factor.
FAQs
Q1: When is Siclotinib expected to receive FDA approval for additional indications?
A1: Pending clinical trial results and FDA review, potential approvals could occur within the next 2-3 years.
Q2: How does Siclotinib’s efficacy compare with Osimertinib?
A2: Clinical trials are ongoing; preliminary data suggest comparable efficacy with a different safety profile. Head-to-head studies are needed for definitive comparisons.
Q3: What discounts are typical in payor negotiations for this drug?
A3: Rebate levels generally range from 10% to 25% of the list price, varying by payer and contract terms.
Q4: Could biosimilars impact Siclotinib’s pricing?
A4: Biosimilars entering the market typically reduce prices by 10-30% over time, depending on market acceptance and regulatory pathways.
Q5: What are the primary drivers for market growth?
A5: Increased genetic testing identifying eligible patients, enhanced clinical efficacy, broader indication approvals, and improved diagnostic tools.
References
[1] Global Data. (2022). NSCLC targeted therapy market report.
